28. October 2009 06:45
Research and Markets (http://www.researchandmarkets.com/research/f10fda/commercial_insight) has announced the addition of the "Commercial Insight: Hormonal Contraceptives - Look Beyond Oral Contraception for a Competitive Edge" report to their offering.
Since the 1960s, hormonal contraceptives have been widely used as effective birth control in the developed world. Although they are mainly used to prevent pregnancies, they can be used for treating other conditions such as acne, endometriosis, and polycystic ovarian syndrome. In 2008, the hormonal contraceptives market was worth $6.2 billion across the seven major pharmaceutical countries.
Scope
- Analysis of the global hormonal contraceptive prescriptions from 200408, split by geographical region, drug class, indication, and brand.
- Discussion of key commercial opportunities and threats in the US, Japan, and five major European markets.
- In depth profiles of key current hormonal contraceptive brands and pipeline agents with SWOT analyses and country-specific sales forecasts to 2018.
- Detailed analysis of key developer trends, strategies and portfolios including a case study of Bayer-Schering's Yasmin franchise.
Highlights of this title
- Sales of hormonal contraceptives in the seven major markets accounted for 68% of the global market value. Over the forecast period 20092018, the market is expected to grow due to the launch of novel natural estrogen products, which will be well received in the US in particular, and the launch of new prescription emergency contraceptives in the EU.
- The market offers opportunities for current and future market players. In addition to indication expansions, there is the need to develop delivery mechanisms that will increase compliance and efficacy. However, the current market environment poses several threats to market growth such as the high litigation pressure and the need to cut sales forces.
- Marketing is a key tool for companies in this market to increase sales of their brands. Datamonitor recommends that companies should also focus on marketing the secondary benefits of taking hormonal contraceptives, such as the decreased risk of gynecological cancers, to increase acceptance of contraceptives.
Key reasons to purchase this title
- Understand historical (200408) and future (20092018) hormonal contraceptive drug market dynamics and competitive environment.
- Gain insight into the main opportunities and threats specific to the hormonal contraceptive market.
- Evaluate the sales forecasts of marketed, generic, and key pipeline drugs to 2018 in the US, Japan, France, Germany, Italy, Spain, and the UK.
Source: Datamonitor
Subscribe